

Addiction Medicine Boards Practice Test (Sample)

Study Guide



Everything you need from our exam experts!

Copyright © 2025 by Examzify - A Kaluba Technologies Inc. product.

ALL RIGHTS RESERVED.

No part of this book may be reproduced or transferred in any form or by any means, graphic, electronic, or mechanical, including photocopying, recording, web distribution, taping, or by any information storage retrieval system, without the written permission of the author.

Notice: Examzify makes every reasonable effort to obtain from reliable sources accurate, complete, and timely information about this product.

SAMPLE

Questions

SAMPLE

- 1. What is the mechanism of action for Flumazenil?**
 - A. Agonist at GABA receptors**
 - B. Partial agonist at GABA receptor with weak binding affinity**
 - C. Antagonist at NMDA receptors**
 - D. Full antagonist at GABA receptors**
- 2. Which of the following symptoms is NOT part of cannabis withdrawal syndrome?**
 - A. Sleep difficulty**
 - B. Irritability**
 - C. Increased appetite**
 - D. Restlessness**
- 3. Which metabolites are expected for oxycodone on confirmatory urine testing?**
 - A. Oxycodone, Hydromorphone**
 - B. Oxycodone, Morphine**
 - C. Oxycodone, Oxymorphone**
 - D. Oxymorphone, Codeine**
- 4. What is a reliable test to detect recent THC use?**
 - A. Blood alcohol level**
 - B. THC:creatinine ratio**
 - C. Urine pH test**
 - D. Hair follicle test**
- 5. What are tramadol's two specific side effects compared to other opioids?**
 - A. Nausea and vomiting**
 - B. Seizures and serotonin syndrome**
 - C. Constipation and respiratory depression**
 - D. Allergic reactions and liver toxicity**

- 6. Which of the following is a potential adverse effect of smoking during pregnancy?**
- A. Increased birth weight**
 - B. Increased risk of SIDS**
 - C. Decreased incidence of preterm birth**
 - D. No impact on pregnancy outcomes**
- 7. What was the intent of the Pure Food and Drug Act enacted in 1906?**
- A. To prohibit the manufacture of illicit drugs**
 - B. To establish the FDA for regulatory purposes**
 - C. To provide addiction treatment programs**
 - D. To allow free trade of pharmaceuticals**
- 8. Which side effect is commonly associated with bupropion?**
- A. Nausea**
 - B. Increased appetite**
 - C. Seizures**
 - D. Constipation**
- 9. What strength of nicotine gum should a patient use if they smoke their first cigarette within 30 minutes of waking?**
- A. 2 mg**
 - B. 4 mg**
 - C. 6 mg**
 - D. 8 mg**
- 10. What type of drug is mescaline/peyote classified as?**
- A. Stimulant**
 - B. Hallucinogen**
 - C. Depressant**
 - D. Opioid**

Answers

SAMPLE

1. B
2. C
3. C
4. B
5. B
6. B
7. B
8. C
9. B
10. B

SAMPLE

Explanations

SAMPLE

1. What is the mechanism of action for Flumazenil?

- A. Agonist at GABA receptors
- B. Partial agonist at GABA receptor with weak binding affinity**
- C. Antagonist at NMDA receptors
- D. Full antagonist at GABA receptors

Flumazenil functions primarily as a competitive antagonist at the benzodiazepine site of the GABA-A receptor. Its action is to reverse the effects of benzodiazepines, making it useful in situations of benzodiazepine overdose. Flumazenil does not activate the receptor; rather, it prevents benzodiazepines from binding to their site, leading to an alleviation of their sedative effects. While the answer provided mentions it as a "partial agonist with weak binding affinity," it is crucial to clarify that flumazenil is better classified as an antagonist. This means it blocks receptor activity rather than activating it but does not exhibit classic antagonistic characteristics such as being a full antagonist. Its role is to counteract the effects of full agonists rather than having agonistic effects itself. Understanding the mechanism of flumazenil is essential for its application in clinical settings, particularly in managing benzodiazepine overdose situations. Differentiating between agonist and antagonist activities at the GABA receptor is fundamental in medication management in addiction medicine.

2. Which of the following symptoms is NOT part of cannabis withdrawal syndrome?

- A. Sleep difficulty
- B. Irritability
- C. Increased appetite**
- D. Restlessness

Cannabis withdrawal syndrome can manifest with several specific symptoms when an individual who has developed a dependence on cannabis suddenly reduces or stops its use. The symptoms typically include sleep difficulty, irritability, and restlessness. These symptoms result from the physiological and psychological adjustments the brain must make after the cessation of the substance, which has influenced neurotransmitter systems over time. Increased appetite is interestingly not part of the withdrawal syndrome. In fact, during withdrawal, individuals may experience a decrease in appetite. This is contrasted with cannabis use, where users often report an increased appetite, commonly referred to as "the munchies." Understanding this distinction is essential for recognizing the different stages of cannabis use and withdrawal, as the symptoms experienced during withdrawal can significantly differ from those experienced while actively using the drug. This knowledge can help healthcare professionals provide appropriate support and interventions for individuals undergoing cannabis withdrawal.

3. Which metabolites are expected for oxycodone on confirmatory urine testing?

- A. Oxycodone, Hydromorphone
- B. Oxycodone, Morphine
- C. Oxycodone, Oxymorphone**
- D. Oxymorphone, Codeine

The correct answer involves understanding the metabolic processes of oxycodone and the substances that are produced from its breakdown. Oxycodone is primarily metabolized in the liver, where it undergoes various enzymatic processes. The most notable metabolites produced include oxymorphone, which is an active metabolite of oxycodone. Therefore, when performing confirmatory urine testing for oxycodone, one would indeed expect to find oxycodone itself along with its metabolite, oxymorphone. The presence of oxymorphone in the urine is particularly significant as it can indicate the use of oxycodone specifically, distinguishing it from other opioids. This is particularly relevant in clinical and legal settings where the identification of specific opioids and their metabolites can impact patient care and drug testing protocols. In contrast, while hydromorphone may be detected in the urine, it is not a direct metabolite of oxycodone. Similarly, morphine is not a metabolite of oxycodone either; it is produced primarily from the breakdown of codeine or heroin, making its presence unrelated to oxycodone use. As such, the correct pairing for confirmatory testing of oxycodone would accurately include both oxycodone and its significant metabolite

4. What is a reliable test to detect recent THC use?

- A. Blood alcohol level
- B. THC:creatinine ratio**
- C. Urine pH test
- D. Hair follicle test

The THC:creatinine ratio is a reliable test for detecting recent THC use because it helps to standardize the concentration of THC in urine, taking into account the dilution that can occur in the specimen due to hydration levels of the individual being tested. This ratio is particularly useful in determining the presence of THC metabolites in urine shortly after cannabis use. Testing for THC in urine relies on the detection of its metabolites, primarily 11-nor-9-carboxy-THC (THC-COOH), which can remain in the body for varying lengths of time depending on factors such as frequency of use and individual metabolism. The THC:creatinine ratio can help improve the accuracy of the test results, particularly for those individuals who may have a higher or lower urine concentration due to fluid intake. In contrast, methods such as blood alcohol levels, urine pH tests, and hair follicle tests do not effectively provide information about recent THC use. Blood alcohol level tests are used to measure alcohol consumption rather than THC. Urine pH tests do not specifically indicate THC use and serve other diagnostic purposes. Hair follicle tests can detect substance use over a longer period (typically months) but are not reliable for identifying recent use, as hair growth takes

5. What are tramadol's two specific side effects compared to other opioids?

- A. Nausea and vomiting**
- B. Seizures and serotonin syndrome**
- C. Constipation and respiratory depression**
- D. Allergic reactions and liver toxicity**

Tramadol is a unique opioid analgesic that has a dual mechanism of action. In addition to its opioid receptor agonist activity, tramadol inhibits the reuptake of norepinephrine and serotonin. This mechanism contributes to its analgesic effects but also establishes a risk profile that is somewhat different from that of traditional opioids. One of the significant side effects associated with tramadol is the potential to induce seizures. This risk arises particularly in situations where tramadol is used in higher doses or in conjunction with other medications that lower the seizure threshold. Additionally, tramadol has been linked to serotonin syndrome, a potentially life-threatening condition resulting from excessive serotonergic activity in the central nervous system. This risk can be heightened when tramadol is combined with other serotonergic drugs, such as SSRIs or SNRIs. These specific side effects—seizures and serotonin syndrome—distinguish tramadol from other opioids, which typically present with side effects such as constipation, respiratory depression, nausea, and vomiting, but do not carry the same risk for seizure activity or serotonergic effects. This unique profile is essential for healthcare providers to consider when prescribing medication for pain management, particularly in patients who may be at higher risk for either of these complications.

6. Which of the following is a potential adverse effect of smoking during pregnancy?

- A. Increased birth weight**
- B. Increased risk of SIDS**
- C. Decreased incidence of preterm birth**
- D. No impact on pregnancy outcomes**

Smoking during pregnancy is associated with several adverse effects, and one significant risk is the increased risk of Sudden Infant Death Syndrome (SIDS). SIDS is the sudden, unexplained death of an otherwise healthy infant, typically during sleep. Numerous studies have shown a strong correlation between maternal smoking and SIDS, indicating that babies exposed to tobacco smoke before and after birth are at a higher risk for this tragic outcome. This is thought to be due to the effects of nicotine and other harmful substances in cigarettes that can impact fetal development and the newborn's respiratory system. In contrast, the other options present assertions that do not align with established medical knowledge: smoking is not associated with increased birth weight; it is more likely to contribute to lower birth weights due to placental insufficiency and other complications. Furthermore, smoking is associated with an increased risk of preterm birth rather than a decrease. Similarly, it has widely recognized detrimental impacts on pregnancy, contradicting the idea that it has no impact on pregnancy outcomes. Thus, the increased risk of SIDS stands out as a critical concern for maternal and fetal health associated with smoking during pregnancy.

7. What was the intent of the Pure Food and Drug Act enacted in 1906?

- A. To prohibit the manufacture of illicit drugs**
- B. To establish the FDA for regulatory purposes**
- C. To provide addiction treatment programs**
- D. To allow free trade of pharmaceuticals**

The intent of the Pure Food and Drug Act enacted in 1906 was to establish the foundation for federal regulation of food and drugs in the United States, effectively leading to the creation of the Food and Drug Administration (FDA). This landmark legislation aimed to ensure that the public could trust the safety and efficacy of consumable products. It mandated that food and drugs be accurately labeled and free of harmful substances, which addressed the widespread issues of adulteration and misbranding at that time. The act focused on protecting consumers from unsanitary and unsafe products, setting a precedent for future regulatory efforts in the pharmacological and food industries. While it did not directly establish the FDA at that moment, it laid the groundwork for the organization to evolve and enforce regulations regarding drug safety and effectiveness, making option B the correct interpretation of the act's intent.

8. Which side effect is commonly associated with bupropion?

- A. Nausea**
- B. Increased appetite**
- C. Seizures**
- D. Constipation**

Bupropion is an atypical antidepressant that is primarily used to treat major depressive disorder and as an aid for smoking cessation. One notable side effect of bupropion is the increased risk of seizures, particularly at higher doses or in individuals with certain risk factors such as a history of seizures, eating disorders, or alcohol/substance withdrawal. This side effect is attributed to its mechanism of action, which involves the inhibition of dopamine and norepinephrine reuptake but does not affect serotonin levels. The risk of seizures is a significant concern with bupropion, especially when the recommended maximum daily dose is exceeded. Understanding this side effect is crucial for medical professionals when prescribing bupropion, as it allows them to monitor for potential complications and guide patient management accordingly. The other side effects, while possible, do not carry the same level of risk associated with seizures, which is why identifying it as a commonly associated side effect is important in the context of using this medication.

9. What strength of nicotine gum should a patient use if they smoke their first cigarette within 30 minutes of waking?

- A. 2 mg
- B. 4 mg**
- C. 6 mg
- D. 8 mg

For individuals who smoke their first cigarette within 30 minutes of waking, it is recommended to use a higher strength of nicotine replacement therapy, specifically 4 mg of nicotine gum. This recommendation is based on the concept of nicotine dependence, which is often assessed by the time to first cigarette after waking. Those who smoke within the first half hour are typically more dependent on nicotine and may require a higher dose to effectively manage withdrawal symptoms and cravings. Using a lower strength, such as 2 mg, might not suffice for these individuals, as it may not provide adequate nicotine to alleviate cravings and withdrawal symptoms linked to their higher level of dependence. The 4 mg option is designed to address these needs and help facilitate a more successful quit attempt by providing sufficient nicotine while minimizing side effects associated with excessive dosing. Hence, patients who are more reliant on nicotine due to their early morning smoking habits are advised to start with the 4 mg gum to increase their chances of quitting successfully.

10. What type of drug is mescaline/peyote classified as?

- A. Stimulant
- B. Hallucinogen**
- C. Depressant
- D. Opioid

Mescaline, found in the peyote cactus, is classified as a hallucinogen due to its ability to alter perception, mood, and cognitive processes. Hallucinogens are substances that can cause significant changes in sensory experiences, thought patterns, and emotions, often leading to visual and auditory hallucinations. Mescaline specifically affects serotonin receptors in the brain, contributing to its psychoactive effects. Understanding the classification of mescaline as a hallucinogen is important in the context of addiction medicine, as the management of individuals using such substances requires different approaches compared to those used for stimulants, depressants, or opioids. This distinction is essential for developing appropriate treatment strategies and educational resources for patients.